A phase II study of recombinant interleukin-2 with or without recombinant interferon-β in non-hodgkin's lymphoma. a study of the cancer and leukemia group B

David B. Duggan, Maria Teresa Santarelli, Kenneth Zamkoff, Stuart Lichtman, John Ellerton, Robert Cooper, Bernard Poiesz, James R. Anderson, Clara D. Bloomfield, Bruce A. Peterson, Arlan J. Gottlieb

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Interleukin-2 (IL-2) and interferon-β (IFN-β) have demonstrated activity against lymphoid malignancies, presumably mediated by the augmentation of lymphokine-activated killer (LAK) cell and natural killer (NK) cell activity. There is in vitro and in vivo evidence to suggest that the combination of IL-2 and IFN-β is synergistic. The Cancer and Leukemia Group B (CALGB) conducted a randomized phase II trial of IL-2 with or without IFN-β in 49 patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). Overall toxicity was severe, with 17 patients experiencing life-threatening toxicity. Three patients had treatment-related deaths. Responses were noted in seven patients (17%). There were no meaningful differences between treatment arms in toxicity profile, response rate, or modulation of in vivo NK and LAK activity. We conclude that IL-2 with or without IFN-β is not effective therapy for NHL in the doses and schedule used in this study.

Original languageEnglish (US)
Pages (from-to)115-122
Number of pages8
JournalJournal of Immunotherapy
Volume12
Issue number2
DOIs
StatePublished - Aug 1992

Keywords

  • Interferon-β
  • Interleukin- 2
  • Lymphokine-activated killer cells
  • Natural killer cells
  • Non-Hodgkin' s lymphoma

Fingerprint Dive into the research topics of 'A phase II study of recombinant interleukin-2 with or without recombinant interferon-β in non-hodgkin's lymphoma. a study of the cancer and leukemia group B'. Together they form a unique fingerprint.

Cite this